Factors associated with screening or treatment initiation among male United States veterans at risk for osteoporosis fracture

Bone

Volumn 50, Issue 4, 2012, Pages 983-988

  Nelson, Richard E ^a,b   Nebeker, Jonathan R ^a,b   Sauer, Brian C ^a,b   LaFleur, Joanne ^a,c  

^a Affairs Medical Center   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Bisphosphonate; BMD; Osteoporosis; Prognostic modeling; Veterans

Indexed keywords

ANTIANDROGEN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; FINASTERIDE; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NARCOTIC ANALGESIC AGENT; PSYCHOTROPIC AGENT; SPIRONOLACTONE; TESTOSTERONE; THIAZIDE DIURETIC AGENT;

AGED; ALCOHOL ABUSE; ARTICLE; BODY MASS; BONE DENSITY; FALLING; FRAGILITY FRACTURE; HUMAN; MALE; NEOPLASM; OSTEOPOROSIS; PROGNOSIS; RHEUMATOID ARTHRITIS; SCREENING; SMOKING; THYROID DISEASE; UNDERWEIGHT; UNITED STATES; VETERAN;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MASS SCREENING; OSTEOPOROTIC FRACTURES; PRIMARY HEALTH CARE; RISK FACTORS; UNITED STATES; VETERANS;

EID: 84858017055     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.11.014     Document Type: Article

References (42)

1. Looker A.C., Orwoll E.S., Johnston C.C., et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res Nov 1997, 12(11):1761-1768.
2. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res Mar 2007, 22(3):465-475.
3. Official positions of the International Society for Clinical Densitrometry 2007, International Society for Clinical Densitrometry, West Hartdord, CT.
4. Clinician's guide to prevention and treatment of osteoporosis 2010, National Osteoporosis Foundation, Washington DC.
5. Morris C.A., Cabral D., Cheng H., et al. Patterns of bone mineral density testing: current guidelines, testing rates, and interventions. J Gen Intern Med Jul 2004, 19(7):783-790.
6. National Committee for Quality Assurance Osteoporosis management in women who had a fracture: percentage of women 67 years of age and older who suffered a fracture, and who had either a bone mineral density (BMD) test or prescription for a drug to treat or prevent osteoporosis in the six months after the fracture 2007, National Committee for Quality Assurance, Washington, D.C.
7. Feldstein A.C., Nichols G., Orwoll E., et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int Aug 2005, 16(8):953-962.
8. Andrade S.E., Majumdar S.R., Chan K.A., et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003, 163(17):2052-2057.
9. Kiebzak G.M., Beinart G.A., Perser K., Ambrose C.G., Siff S.J., Heggeness M.H. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002, 162(19):2217-2222.
10. Wehren L.E., Hawkes W.G., Orwig D.L., Hebel J.R., Zimmerman S.I., Magaziner J. Gender differences in mortality after hip fracture: the role of infection. J Bone Miner Res Dec 2003, 18(12):2231-2237.
11. Diamond T.H., Thornley S.W., Sekel R., Smerdely P. Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 1997, 167(8):412-415.
12. Vanasse A., Dagenais P., Niyonsenga T., Gregoire J.P., Courteau J., Hemiari A. Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec. BMC Musculoskelet Disord 2005, 6:33.
13. Nayak S., Roberts M.S., Greenspan S.L. Factors associated with diagnosis and treatment of osteoporosis in older adults. Osteoporos Int 2009, 20:1963-1967.
14. Solomon D.H., Katz J.N., Jacobs J.P., La Tourette A.M., Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum Dec 2002, 46(12):3136-3142.
15. Nayak S., Roberts M.S., Greenspan S.L. Factors associated with osteoporosis screening and recommendations for osteoporosis screening in older adults. J Gen Intern Med May 2009, 24(5):585-591.
16. Steyerberg E.W. Clinical prediction models: a practical approach to development, validation, and updating 2009, Springer, New York.
17. Siris E.S., Miller P.D., Barrett-Connor E., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001, 286(22):2815-2822.
18. Dawson-Hughes B. A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 2008, 93(7):2463-2465.
19. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348(9041):1535-1541.
20. Black D.M., Thompson D.E. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial. Int J Clin Pract Suppl Apr 1999, 101:46-50.
21. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA Dec 23-30 1998, 280(24):2077-2082.
22. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
23. Koike T., Orito Y., Toyoda H., et al. External hip protectors are effective for the elderly with higher-than-average risk factors for hip fractures. Osteoporos Int 2009, 20(9):1613-1620.
24. Lindsay R., Silverman S.L., Cooper C., et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285(3):320-323.
25. Ross P.D. Predicting bone loss and fracture risk with biochemical markers: a review. J Clin Densitom 1999, 2(3):285-294.
26. Adinoff A.D., Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983, 309(5):265-268.
27. Cooper C., Coupland C., Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995, 54(1):49-52.
28. Dykman T.R., Gluck O.S., Murphy W.A., Hahn T.J., Hahn B.H. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985, 28(4):361-368.
29. Hooyman J.R., Melton L.J., Nelson A.M., O'Fallon W.M., Riggs B.L. Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum 1984, 27(12):1353-1361.
30. McDougall R., Sibley J., Haga M., Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994, 21(7):1207-1213.
31. Saag K.G., Koehnke R., Caldwell J.R., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med Feb 1994, 96(2):115-123.
32. Richards J.B., Papaioannou A., Adachi J.D., et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007, 167(2):188-194.
33. Arndt S., Schultz S.K., Turvey C., Petersen A. Screening for alcoholism in the primary care setting: are we talking to the right people?. J Fam Pract Jan 2002, 51(1):41-46.
34. Zeng Q.T., Goryachev S., Weiss S., Sordo M., Murphy S.N., Lazarus R. Extracting principal diagnosis, co-morbidity and smoking status for asthma research: evaluation of a natural language processing system. BMC Med Inform Decis Mak 2006, 6:30.
35. Backus L.I., Boothroyd D.B., Phillips B.R., et al. National quality forum performance measures for HIV/AIDS care: the Department of Veterans Affairs' experience. Arch Intern Med 2010, 170(14):1239-1246.
36. Jackson G.L., Melton L.D., Abbott D.H., et al. Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs. J Clin Oncol 2010, 28(19):3176-3181.
37. Cohen S.M., Kataoka-Yahiro M. Provider adherence to clinical guidelines related to lipid-lowering medications. Mil Med Feb 2010, 175(2):122-126.
38. Choma N.N., Huang R.L., Dittus R.S., Burnham K.E., Roumie C.L. Quality improvement initiatives improve hypertension care among veterans. Circ Cardiovasc Qual Outcomes Jul 2009, 2(4):392-398.
39. Shibli-Rahhal A., Vaughan-Sarrazin M.S., Richardson K., Cram P. Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system. Osteoporos Int 2011 Dec, 22(12):2973-2980.
40. Helmer D., Sambamoorthi U., Shen Y., et al. Opting out of an integrated healthcare system: dual-system use is associated with poorer glycemic control in veterans with diabetes. Prim Care Diabetes Jun 2008, 2(2):73-80.
41. Carey K., Montez-Rath M.E., Rosen A.K., Christiansen C.L., Loveland S., Ettner S.L. Use of VA and Medicare services by dually eligible veterans with psychiatric problems. Health Serv Res Aug 2008, 43(4):1164-1183.
42. Byrne M.M., Kuebeler M., Pietz K., Petersen L.A. Effect of using information from only one system for dually eligible health care users. Med Care Aug 2006, 44(8):768-773.